110 likes | 435 Views
New STA process. Technical Engagement. Jenna Dilkes Programme Manager - Planning and Operations, Technology Appraisals. Technical Engagement – Who? What? Why? When?. Update on new Single Technology Appraisal (STA) process When and why have we included Technical Engagement What is it?
E N D
New STA process Technical Engagement Jenna Dilkes Programme Manager - Planning and Operations, Technology Appraisals
Technical Engagement – Who? What? Why? When? • Update on new Single Technology Appraisal (STA) process • When and why have we included Technical Engagement • What is it? • How will it look? • How can stakeholders get involved? • Post Technical Engagement actions
New Single Technology Appraisal Process (STA) • Introduced in April 2018 https://www.nice.org.uk/process/pmg19/chapter/acknowledgements • Getting to the right decision at the right time
Technical Engagement overview • Additional step in the Technology Appraisal process aiming to pull forward consideration of scientific and technical elements prior to committee * approximate timings
Technical report - response form template • Questions for engagement
How do patient organisations get involved? • Experts • Creation of the Technical Report (if required) • Technical engagement TC • Stakeholder organisations • Responding to Technical Report questions during the engagement stage
Post Technical Engagement • NICE technical team update the technical report • The updated technical report and the technical engagement comments are included in the committee papers (sent 2 weeks prior to the appraisal committee meeting (ACm)) • Committee papers are also published on the NICE website post ACm alongside the ACD or FAD.
New process topics • ID1175 Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation - Committee D • Technical Engagement starts w/c 17.12.18. Committee meeting: 14.02.19 • ID1302 Osimertinib for untreated EGFR-positive non-small-cell lung cancer- Committee D • Technical Engagement starts w/c 14.01.19. Committee meeting: 20.03.19 • ID1318 Ribociclib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative breast cancer – Committee A • Technical Engagement starts w/c 07.01.19. Committee meeting: 12.03.19